Paper · 40227644
From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.
Burns CP and 4 others. Cancers (Basel), 2025. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer. Papers, record 40227644. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40227644
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References180
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,190,111 | Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. | Eur Urol Focus | 2018 | https://conductscience.org/library/papers/30190111 | PubMed |
| 2 | 33,863,885 | An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. | Nat Commun | 2021 | https://conductscience.org/library/papers/33863885 | PubMed |
| 3 | 28,978,000 | PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. | Oncotarget | 2017 | https://conductscience.org/library/papers/28978000 | PubMed |
| 4 | 30,849,371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
| 5 | 32,971,005 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32971005 | PubMed |
| 6 | 35,897,708 | Multiparametric Classification of Non-Muscle Invasive Papillary Urothelial Neoplasms: Combining Morphological, Phenotypical, and Molecular Features for Improved Risk Stratification. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35897708 | PubMed |
| 7 | 31,026,471 | Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. | Hum Pathol | 2019 | https://conductscience.org/library/papers/31026471 | PubMed |
| 8 | 34,330,764 | Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34330764 | PubMed |
| 9 | 29,150,702 | High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. | Cancer Immunol Immunother | 2018 | https://conductscience.org/library/papers/29150702 | PubMed |
| 10 | 28,418,913 | Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28418913 | PubMed |
1 to 10 of 180
See all 180 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,616,005 | Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation. | PLoS One | 2026 | https://conductscience.org/library/papers/41616005 | PubMed |
| 41,471,825 | Exploring EGFR, Nectin-4, and TROP-2 as Therapeutic Targets for Bladder Cancer Photoimmunotherapy. | Molecules | 2025 | https://conductscience.org/library/papers/41471825 | PubMed |
| 40,662,552 | Identification of DNA Replication Stress-Related Genes as Prognostic Biomarkers for Bladder Cancer. | Comb Chem High Throughput Screen | 2026 | https://conductscience.org/library/papers/40662552 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1,493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40227644
GET https://conductscience.org/api/papers/v1/40227644/references?page=2